Fig. 4

Survival probability by MFC-MRD status in patients with ≥ 5%/ < 5% blasts based on morphology at TP2. According to MFC-MRD levels at TP2, patients were stratified into two MFC-MRD-based groups (MFC-MRD < 0.1%; MFC-MRD ≥ 0.1%). EFS (a), OS (b), and CIR (c) of patients with ≥ 5% blasts by morphology according to MFC-MRD prior to the start of consolidation. EFS (d), OS (e), and CIR (f) of patients with < 5% blasts according to the MFC-MRD before consolidation. EFS, event-free survival; OS, overall survival; CIR, cumulative incidence of relapse; MFC, multiparametric flow cytometry; MRD, minimal residual disease, TP2, at the end of the second course of induction (before start of consolidation)